- Home
- MNOV vs TIL Comparison
MNOV vs TIL Comparison
Compare MNOV & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | TIL |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.7M | 74.7M |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MNOV | TIL |
|---|---|---|
| Price | $1.46 | $8.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $8.00 | ★ $125.00 |
| AVG Volume (30 Days) | ★ 73.0K | 21.1K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 52.54 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,360,807.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.13 | $5.67 |
| 52 Week High | $1.96 | $42.75 |
Technical Indicators
Market Signals| Indicator | MNOV | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 50.03 | 46.43 |
| Support Level | $1.24 | $8.14 |
| Resistance Level | $1.62 | $9.27 |
| Average True Range (ATR) | 0.08 | 0.47 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 61.42 | 23.59 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.